Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
World's Best Specialized Hospitals 2021 - Newsweek magazine places Gustave Roussy among the top 5 best cancer hospitals in the world
On
Villejuif, September 24th, 2020
World's Best Specialized Hospitals 2021
Newsweek magazine places Gustave Roussy among the top 5 best cancer hospitals in the world
According to the World’s Best Specialized Hospitals 2021 ranking by Newsweek magazine, Gustave Roussy is in 5th position worldwide and 1st hospital outside of the United States. This ranking emphasizes the international recognition for excellence in care and powerful research performed by the Institute. It also means that patients, whose decision to choose the right hospital is determined mainly by the hospital’s reputation, can be confident and receive in France both the best care and the most effective clinical research.
View this ranking on https://www.newsweek.com/worlds-best-specialized-hospitals-2021/oncology
"We are proud to be one of the world's top 5 cancer centers along with four American giants. This ranking is an important recognition of our savoir-faire and team expertise. Both our medical staff and scientists play an important part in making French healthcare one of the best in the world. Gustave Roussy has the ability to meet all the challenges of the 21st century: to detect, to study, to fight against, to care for and to overcome cancer" explains Professor Jean-Charles Soria, CEO of Gustave Roussy.
This new ranking reinforces Gustave Roussy's international reputation. Honored every year in the Clarivate ranking, with 10 of its experts featuring in the 2019 list of the world's most "Highly cited researchers". Gustave Roussy's physician-scientists are also regularly awarded prizes at international congresses by learned societies or major research organizations or foundations. Knowledge production is intensive, with 1,800 international publications, including more than 60 in highly cited papers (journal impact factor greater than 30).
Today, the Institute is a key player in the world for early trials, immunotherapy and precision medicine clinical trials. Nearly a quarter of Gustave Roussy's patients are part of a clinical study.
Today, by developing its new institutional strategic plan for the next ten years, Gustave Roussy is all geared up for the fight against cancer and the growing complexity of the disease, all for the benefit of their patients. The World's Best Specialized Hospitals 2021 ranking was produced by Newsweek magazine and the world-leading statistics portal and industry ranking provider, Statista, Inc. Together they expanded their expertise by looking for the first time at specialties, ranking the best hospitals in oncology, cardiology and endocrinology.
In total over 40,000 medical experts (doctors, health care professionals and hospital managers) from over 20 countries were invited to participate in an online survey. Participants were asked to recommend hospitals based on their expertise in one primary medical field (e.g. Cardiology for Cardiologists) and were also able to choose another area of expertise in which they were also knowledgeable, (e.g. due to frequent cooperation with other medical fields). These second recommendations had a lower impact than the primary recommendations. The questionnaire did not suggest a list of recommended hospitals; therefore, respondents were free to suggest any hospital they considered recommendable. Self-recommendations were not allowed.
For further information on this survey: https://www.statista-research.com/wp-content/uploads/2020/09/20200910_Worlds-Best-Specialized-Hospitals-2021-Methodology.pdf
▶
pr-newsweek-top-5-24092020.pdf
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
Gold september: two new research programmes launched to tackle childhood cancers
Two of Gustave Roussy’s four new medical and scientific programmes are dedicated to childhood cancers. The first, DECRIPT, aims to improve understanding of the role played by genetics in the development of certain childhood cancers, as well as second cancers that may occur in adulthood. The second, INSPIRE, will draw on the knowledge and techniques already developed at the Institute to create organoids, with the aim of deciphering the mechanisms underlying metastasis and resistance to treatment.
-
Prof. Fabrice Barlesi reappointed at the head of Gustave Roussy, the leading cancer center in France and Europe
By order of Ms. Stéphanie Rist, Minister of Health, Families, Autonomy and Persons with Disabilities, dated 27 July 2026, Professor Fabrice Barlesi has been reappointed as Director General of Gustave Roussy, effective 1 August 2026. At the helm of the Institute for five more years, Prof. Barlesi will continue the transformations undertaken during his first term. This renewal reflects the confidence placed in the project led by the institution to accelerate progress in the fight against cancer, foster and support the development of innovations set to change the future of oncology, and strengthen the influence of one of the world's leading cancer centers.
-
Route du Rhum 2026 Jean Le Cam and Christophe Rateau to sail for Gustave Roussy
For the Route du Rhum - Destination Guadeloupe 2026, Jean Le Cam and Christophe Rateau will sail under the colors of Gustave Roussy, the leading cancer center in France and Europe. Competing respectively in the Vintage and Class40 categories, the two skippers will carry the Institute's mission to the general public, supporting cancer research and raising awareness of prevention, innovation and patient care.
-
Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practice
Owkin and Gustave Roussy, Europe's leading cancer center, today announced a partnership to test K Pro directly within the hospital's real-world clinical and research workflows.
